R&D LSX2026: Endogenous tissue restoration in vascular disease –... Paulo Neves, CMO of Xeltis, discusses transformative implants that enable the natural creation of living and long-lasting vessels.
R&D LSX2026: Non-opioid pain relief and pharma positivity, with ... Mike Cooke, CEO of AmacaThera, spoke with pharmaphorum at the LSX World Congress, including about non-opioid pain relief.
R&D LSX2026: On a therapeutic vision for ocular disease, with Al... Alexander Gebauer, co-founder & executive chairman of Galimedix Therapeutics, discusses transforming treatment of major neurodegenerative eye diseases
R&D BIO-Europe Spring 2026: In conversation with Robert Jacks Robert Jacks, CEO of Sparrow Pharmaceuticals, discusses the company’s work in the cardiometabolic space.
Oncology ASCO 26: Three strong Pfizer Phase 3s, with Johanna Bendell Pharmaphorum caught up with Johanna Bendell, Pfizer’s chief development officer for oncology, to learn about what the company is bringing to ASCO.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
